sas genetic software Search Results


gene exp tspan31 hs00919595 g1  (Thermo Fisher)
91
Thermo Fisher gene exp tspan31 hs00919595 g1
Overexpression of Tetraspanin31 <t>(TSPAN31)</t> in gastric cancer. (A) Expression of TSPAN31 in seven gastric cancer (GC) cell lines compared with the fibroblast cell strain WI‐38. The level of TSPAN31 mRNA was determined by quantitative RT‐PCR in a panel of GC cell lines. Results shown are means ± SD (bars). Black bars represent cell lines, in which upregulation of TSPAN31 mRNA expression was observed and compared with that in WI‐38. The status of a TP53 mutation was the reported status of a TP53 mutation in the database ( http://p53.free.fr/index.html ). M, mutant TP53 ; W, WT TP 53. Note that among TP53 ‐mutated GC cell lines, KATO‐III and HGC27 cells had a p53 gene deletion and a frameshift mutation, respectively. (B) Specific immunostaining of TSPAN31 in a representative primary tumor sample. Based on this result, the intensity scores for TSPAN31 staining were determined as follows: 0, negative; 1, weak; 2, moderate; 3, strong. Kaplan–Meier plots depending on the intensity (C) and proportion (D) scores of specific immunostainings of TSPAN31. The log–rank test was used for statistical analysis; p < 0.05 was considered to be statistically significant. (E) For the scoring of TSPAN31 expression, the intensity and percentage of total cell population (proportion score; 0 < 10%, 10% ≤ 1 < 33%, 33% ≤ 2 < 66%, 66% ≤ 3 ≤ 100%) that expressed TSPAN31 were evaluated for each case. Expression of TSPAN31 was graded as high expression (intensity plus proportion scores ≥4 for tumor cells showing immunopositivity) or low expression (intensity plus proportion scores ≤3 for tumor cells showing immunopositivity). (F) Cancer‐specific survival rates of patients with GC (as determined by Kaplan–Meier plots), depending on TSPAN31 expression
Gene Exp Tspan31 Hs00919595 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sas+genetic+software/Gene+Exp%2E+TSPAN31%2C+Hs00919595_g1/pmc09207375-100-35-53
Average 91 stars, based on 1 article reviews
gene exp tspan31 hs00919595 g1 - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
genetics version 9 2  (STATA Corporation)
99
STATA Corporation genetics version 9 2
Overexpression of Tetraspanin31 <t>(TSPAN31)</t> in gastric cancer. (A) Expression of TSPAN31 in seven gastric cancer (GC) cell lines compared with the fibroblast cell strain WI‐38. The level of TSPAN31 mRNA was determined by quantitative RT‐PCR in a panel of GC cell lines. Results shown are means ± SD (bars). Black bars represent cell lines, in which upregulation of TSPAN31 mRNA expression was observed and compared with that in WI‐38. The status of a TP53 mutation was the reported status of a TP53 mutation in the database ( http://p53.free.fr/index.html ). M, mutant TP53 ; W, WT TP 53. Note that among TP53 ‐mutated GC cell lines, KATO‐III and HGC27 cells had a p53 gene deletion and a frameshift mutation, respectively. (B) Specific immunostaining of TSPAN31 in a representative primary tumor sample. Based on this result, the intensity scores for TSPAN31 staining were determined as follows: 0, negative; 1, weak; 2, moderate; 3, strong. Kaplan–Meier plots depending on the intensity (C) and proportion (D) scores of specific immunostainings of TSPAN31. The log–rank test was used for statistical analysis; p < 0.05 was considered to be statistically significant. (E) For the scoring of TSPAN31 expression, the intensity and percentage of total cell population (proportion score; 0 < 10%, 10% ≤ 1 < 33%, 33% ≤ 2 < 66%, 66% ≤ 3 ≤ 100%) that expressed TSPAN31 were evaluated for each case. Expression of TSPAN31 was graded as high expression (intensity plus proportion scores ≥4 for tumor cells showing immunopositivity) or low expression (intensity plus proportion scores ≤3 for tumor cells showing immunopositivity). (F) Cancer‐specific survival rates of patients with GC (as determined by Kaplan–Meier plots), depending on TSPAN31 expression
Genetics Version 9 2, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sas+genetic+software/STATA+9%2E0/pmc04296186-131-9-21
Average 99 stars, based on 1 article reviews
genetics version 9 2 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
full matching 4 10 software implementation  (STATA Corporation)
99
STATA Corporation full matching 4 10 software implementation
Overexpression of Tetraspanin31 <t>(TSPAN31)</t> in gastric cancer. (A) Expression of TSPAN31 in seven gastric cancer (GC) cell lines compared with the fibroblast cell strain WI‐38. The level of TSPAN31 mRNA was determined by quantitative RT‐PCR in a panel of GC cell lines. Results shown are means ± SD (bars). Black bars represent cell lines, in which upregulation of TSPAN31 mRNA expression was observed and compared with that in WI‐38. The status of a TP53 mutation was the reported status of a TP53 mutation in the database ( http://p53.free.fr/index.html ). M, mutant TP53 ; W, WT TP 53. Note that among TP53 ‐mutated GC cell lines, KATO‐III and HGC27 cells had a p53 gene deletion and a frameshift mutation, respectively. (B) Specific immunostaining of TSPAN31 in a representative primary tumor sample. Based on this result, the intensity scores for TSPAN31 staining were determined as follows: 0, negative; 1, weak; 2, moderate; 3, strong. Kaplan–Meier plots depending on the intensity (C) and proportion (D) scores of specific immunostainings of TSPAN31. The log–rank test was used for statistical analysis; p < 0.05 was considered to be statistically significant. (E) For the scoring of TSPAN31 expression, the intensity and percentage of total cell population (proportion score; 0 < 10%, 10% ≤ 1 < 33%, 33% ≤ 2 < 66%, 66% ≤ 3 ≤ 100%) that expressed TSPAN31 were evaluated for each case. Expression of TSPAN31 was graded as high expression (intensity plus proportion scores ≥4 for tumor cells showing immunopositivity) or low expression (intensity plus proportion scores ≤3 for tumor cells showing immunopositivity). (F) Cancer‐specific survival rates of patients with GC (as determined by Kaplan–Meier plots), depending on TSPAN31 expression
Full Matching 4 10 Software Implementation, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sas+genetic+software/STATA+10%2E0/pm31559905-21-13-30
Average 99 stars, based on 1 article reviews
full matching 4 10 software implementation - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


Overexpression of Tetraspanin31 (TSPAN31) in gastric cancer. (A) Expression of TSPAN31 in seven gastric cancer (GC) cell lines compared with the fibroblast cell strain WI‐38. The level of TSPAN31 mRNA was determined by quantitative RT‐PCR in a panel of GC cell lines. Results shown are means ± SD (bars). Black bars represent cell lines, in which upregulation of TSPAN31 mRNA expression was observed and compared with that in WI‐38. The status of a TP53 mutation was the reported status of a TP53 mutation in the database ( http://p53.free.fr/index.html ). M, mutant TP53 ; W, WT TP 53. Note that among TP53 ‐mutated GC cell lines, KATO‐III and HGC27 cells had a p53 gene deletion and a frameshift mutation, respectively. (B) Specific immunostaining of TSPAN31 in a representative primary tumor sample. Based on this result, the intensity scores for TSPAN31 staining were determined as follows: 0, negative; 1, weak; 2, moderate; 3, strong. Kaplan–Meier plots depending on the intensity (C) and proportion (D) scores of specific immunostainings of TSPAN31. The log–rank test was used for statistical analysis; p < 0.05 was considered to be statistically significant. (E) For the scoring of TSPAN31 expression, the intensity and percentage of total cell population (proportion score; 0 < 10%, 10% ≤ 1 < 33%, 33% ≤ 2 < 66%, 66% ≤ 3 ≤ 100%) that expressed TSPAN31 were evaluated for each case. Expression of TSPAN31 was graded as high expression (intensity plus proportion scores ≥4 for tumor cells showing immunopositivity) or low expression (intensity plus proportion scores ≤3 for tumor cells showing immunopositivity). (F) Cancer‐specific survival rates of patients with GC (as determined by Kaplan–Meier plots), depending on TSPAN31 expression

Journal: Cancer Science

Article Title: Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer

doi: 10.1111/cas.15342

Figure Lengend Snippet: Overexpression of Tetraspanin31 (TSPAN31) in gastric cancer. (A) Expression of TSPAN31 in seven gastric cancer (GC) cell lines compared with the fibroblast cell strain WI‐38. The level of TSPAN31 mRNA was determined by quantitative RT‐PCR in a panel of GC cell lines. Results shown are means ± SD (bars). Black bars represent cell lines, in which upregulation of TSPAN31 mRNA expression was observed and compared with that in WI‐38. The status of a TP53 mutation was the reported status of a TP53 mutation in the database ( http://p53.free.fr/index.html ). M, mutant TP53 ; W, WT TP 53. Note that among TP53 ‐mutated GC cell lines, KATO‐III and HGC27 cells had a p53 gene deletion and a frameshift mutation, respectively. (B) Specific immunostaining of TSPAN31 in a representative primary tumor sample. Based on this result, the intensity scores for TSPAN31 staining were determined as follows: 0, negative; 1, weak; 2, moderate; 3, strong. Kaplan–Meier plots depending on the intensity (C) and proportion (D) scores of specific immunostainings of TSPAN31. The log–rank test was used for statistical analysis; p < 0.05 was considered to be statistically significant. (E) For the scoring of TSPAN31 expression, the intensity and percentage of total cell population (proportion score; 0 < 10%, 10% ≤ 1 < 33%, 33% ≤ 2 < 66%, 66% ≤ 3 ≤ 100%) that expressed TSPAN31 were evaluated for each case. Expression of TSPAN31 was graded as high expression (intensity plus proportion scores ≥4 for tumor cells showing immunopositivity) or low expression (intensity plus proportion scores ≤3 for tumor cells showing immunopositivity). (F) Cancer‐specific survival rates of patients with GC (as determined by Kaplan–Meier plots), depending on TSPAN31 expression

Article Snippet: The abundance of mRNA was measured by quantitative PCR using a StepOnePlus PCR System (Applied Biosystems), and cycle threshold (Ct) values were calculated with StepOne Software version 2.0 (Applied Biosystems) using TaqMan Gene Expression Assays (Hs00919595_g1 for TSPAN31 , Hs00170423_m1 for E ‐ cadherin , Hs00958111_m1 for Vimentin , Hs00960489_m1 for ABCC2 ; Applied Biosystems) according to the manufacturer’s instructions.

Techniques: Over Expression, Expressing, Quantitative RT-PCR, Mutagenesis, Immunostaining, Staining

Associations between clinicopathologic features and expression of Tetraspanin31 (TSPAN31) in gastric cancer patients

Journal: Cancer Science

Article Title: Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer

doi: 10.1111/cas.15342

Figure Lengend Snippet: Associations between clinicopathologic features and expression of Tetraspanin31 (TSPAN31) in gastric cancer patients

Article Snippet: The abundance of mRNA was measured by quantitative PCR using a StepOnePlus PCR System (Applied Biosystems), and cycle threshold (Ct) values were calculated with StepOne Software version 2.0 (Applied Biosystems) using TaqMan Gene Expression Assays (Hs00919595_g1 for TSPAN31 , Hs00170423_m1 for E ‐ cadherin , Hs00958111_m1 for Vimentin , Hs00960489_m1 for ABCC2 ; Applied Biosystems) according to the manufacturer’s instructions.

Techniques: Expressing

Multivariate analysis using Cox proportional hazards model for cancer‐specific survival among gastric cancer patients who received gastrectomy

Journal: Cancer Science

Article Title: Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer

doi: 10.1111/cas.15342

Figure Lengend Snippet: Multivariate analysis using Cox proportional hazards model for cancer‐specific survival among gastric cancer patients who received gastrectomy

Article Snippet: The abundance of mRNA was measured by quantitative PCR using a StepOnePlus PCR System (Applied Biosystems), and cycle threshold (Ct) values were calculated with StepOne Software version 2.0 (Applied Biosystems) using TaqMan Gene Expression Assays (Hs00919595_g1 for TSPAN31 , Hs00170423_m1 for E ‐ cadherin , Hs00958111_m1 for Vimentin , Hs00960489_m1 for ABCC2 ; Applied Biosystems) according to the manufacturer’s instructions.

Techniques: Expressing

Associations between expression of Tetraspanin31 (TSPAN31) and disease recurrence in gastric cancer patients with gastrectomy

Journal: Cancer Science

Article Title: Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer

doi: 10.1111/cas.15342

Figure Lengend Snippet: Associations between expression of Tetraspanin31 (TSPAN31) and disease recurrence in gastric cancer patients with gastrectomy

Article Snippet: The abundance of mRNA was measured by quantitative PCR using a StepOnePlus PCR System (Applied Biosystems), and cycle threshold (Ct) values were calculated with StepOne Software version 2.0 (Applied Biosystems) using TaqMan Gene Expression Assays (Hs00919595_g1 for TSPAN31 , Hs00170423_m1 for E ‐ cadherin , Hs00958111_m1 for Vimentin , Hs00960489_m1 for ABCC2 ; Applied Biosystems) according to the manufacturer’s instructions.

Techniques: Expressing

Suppression of malignant activities in gastric cancer cells by knockdown of Tetraspanin31 (TSPAN31). (A) Effects of TSPAN31 knockdown on cell proliferation at the indicated times by siRNA (siRNA‐TSPAN31) compared with those of control siRNA in NUGC4 (WT TP53 ) and MKN74 (mutant TP53 ) cell lines. (B) Representative results of the population in each phase of the cell cycle in each cell line, as assessed by FACS at 72 h posttreatment with siRNA. (C) Representative results of the apoptosis assay in gastric cancer cells 72 h after treatment with siRNA. (D) TSPAN31 overexpression facilitated cell proliferation at the indicated times in MKN45 (WT TP53 ), HGC27 (mutant TP53 ), and MKN7 (mutant TP53 ) cell lines. Western blot analyses showed that overexpression of TSPAN31 induced phosphorylation activation of AKT. Expression of TSPAN31 protein was confirmed by western blotting using anti‐HaloTag Ab. (E) Reduction of tumor volumes of xenografts implanted NUGC4 cells with transfection of siRNA‐Luc ( n = 4) or siRNA‐TSPAN31 ( n = 4). Subcutaneous injection of siRNA‐Luc or siRNA‐TSPAN31 with atelocollagen around the tumor was repeated once a week for 2 weeks after tumor cell implantation. Results shown are means ± SD (bars) for quadruplicate experiments. Mann–Whitney U ‐test was used for statistical analysis. * p < 0.05

Journal: Cancer Science

Article Title: Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer

doi: 10.1111/cas.15342

Figure Lengend Snippet: Suppression of malignant activities in gastric cancer cells by knockdown of Tetraspanin31 (TSPAN31). (A) Effects of TSPAN31 knockdown on cell proliferation at the indicated times by siRNA (siRNA‐TSPAN31) compared with those of control siRNA in NUGC4 (WT TP53 ) and MKN74 (mutant TP53 ) cell lines. (B) Representative results of the population in each phase of the cell cycle in each cell line, as assessed by FACS at 72 h posttreatment with siRNA. (C) Representative results of the apoptosis assay in gastric cancer cells 72 h after treatment with siRNA. (D) TSPAN31 overexpression facilitated cell proliferation at the indicated times in MKN45 (WT TP53 ), HGC27 (mutant TP53 ), and MKN7 (mutant TP53 ) cell lines. Western blot analyses showed that overexpression of TSPAN31 induced phosphorylation activation of AKT. Expression of TSPAN31 protein was confirmed by western blotting using anti‐HaloTag Ab. (E) Reduction of tumor volumes of xenografts implanted NUGC4 cells with transfection of siRNA‐Luc ( n = 4) or siRNA‐TSPAN31 ( n = 4). Subcutaneous injection of siRNA‐Luc or siRNA‐TSPAN31 with atelocollagen around the tumor was repeated once a week for 2 weeks after tumor cell implantation. Results shown are means ± SD (bars) for quadruplicate experiments. Mann–Whitney U ‐test was used for statistical analysis. * p < 0.05

Article Snippet: The abundance of mRNA was measured by quantitative PCR using a StepOnePlus PCR System (Applied Biosystems), and cycle threshold (Ct) values were calculated with StepOne Software version 2.0 (Applied Biosystems) using TaqMan Gene Expression Assays (Hs00919595_g1 for TSPAN31 , Hs00170423_m1 for E ‐ cadherin , Hs00958111_m1 for Vimentin , Hs00960489_m1 for ABCC2 ; Applied Biosystems) according to the manufacturer’s instructions.

Techniques: Knockdown, Control, Mutagenesis, Apoptosis Assay, Over Expression, Western Blot, Phospho-proteomics, Activation Assay, Expressing, Transfection, Injection, MANN-WHITNEY

Molecular mechanisms by which the overexpression of Tetraspanin31 (TSPAN31) contributes to malignant potential in gastric cancer (GC) cells. (A) Knockdown of TSPAN31 by transfection with siRNA‐TSPAN31 suppressed the phosphorylation activation of AKT, induced the production of p21, suppressed the production of cyclin D1, and induced phosphorylation inactivation of retinoblastoma (Rb) in NUGC4 (WT TP53 ) and MKN74 (mutant TP5 3) cells. Moreover, knockdown of TSPAN31 also induced the cleavage of caspase 3 and poly(ADP‐ribose) polymerase (PARP) in GC cells. (B) A hypothetical model of the overexpression or activation of TSPAN31 in GC cells

Journal: Cancer Science

Article Title: Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer

doi: 10.1111/cas.15342

Figure Lengend Snippet: Molecular mechanisms by which the overexpression of Tetraspanin31 (TSPAN31) contributes to malignant potential in gastric cancer (GC) cells. (A) Knockdown of TSPAN31 by transfection with siRNA‐TSPAN31 suppressed the phosphorylation activation of AKT, induced the production of p21, suppressed the production of cyclin D1, and induced phosphorylation inactivation of retinoblastoma (Rb) in NUGC4 (WT TP53 ) and MKN74 (mutant TP5 3) cells. Moreover, knockdown of TSPAN31 also induced the cleavage of caspase 3 and poly(ADP‐ribose) polymerase (PARP) in GC cells. (B) A hypothetical model of the overexpression or activation of TSPAN31 in GC cells

Article Snippet: The abundance of mRNA was measured by quantitative PCR using a StepOnePlus PCR System (Applied Biosystems), and cycle threshold (Ct) values were calculated with StepOne Software version 2.0 (Applied Biosystems) using TaqMan Gene Expression Assays (Hs00919595_g1 for TSPAN31 , Hs00170423_m1 for E ‐ cadherin , Hs00958111_m1 for Vimentin , Hs00960489_m1 for ABCC2 ; Applied Biosystems) according to the manufacturer’s instructions.

Techniques: Over Expression, Knockdown, Transfection, Phospho-proteomics, Activation Assay, Mutagenesis

Suppression of migration, invasion, and epithelial–mesenchymal transition (EMT) in gastric cancer (GC) cells by knockdown of Tetraspanin31 (TSPAN31). (A) Knockdown TSPAN31 by siRNA‐TSPAN31 suppressed migration and invasion in NUGC4 (WT TP53 ) and MKN74 (mutant TP53 ) cell lines. Bottom graphs show means ± SD (bars; n = 4). Mann–Whitney U ‐test test was used for statistical analysis. p < 0.05 was considered statistically significant. (B) Identification of appropriate GC cell lines for an investigation into whether knockdown of TSPAN31 can suppress EMT. The panel mRNA expression levels of E ‐ cadherin and Vimentin were investigated, and the Vimentin / E ‐ cadherin ratio was calculated. In MKN7 cells, Vimentin mRNA expression was higher, and E ‐ cadherin mRNA expression was lower compared to other TSPAN31‐overexpressing cell lines. (C) Knockdown of TSPAN31 induced significant morphological change, increased the expression of E‐cadherin protein, and reduced the expression of Vimentin and Snail proteins

Journal: Cancer Science

Article Title: Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer

doi: 10.1111/cas.15342

Figure Lengend Snippet: Suppression of migration, invasion, and epithelial–mesenchymal transition (EMT) in gastric cancer (GC) cells by knockdown of Tetraspanin31 (TSPAN31). (A) Knockdown TSPAN31 by siRNA‐TSPAN31 suppressed migration and invasion in NUGC4 (WT TP53 ) and MKN74 (mutant TP53 ) cell lines. Bottom graphs show means ± SD (bars; n = 4). Mann–Whitney U ‐test test was used for statistical analysis. p < 0.05 was considered statistically significant. (B) Identification of appropriate GC cell lines for an investigation into whether knockdown of TSPAN31 can suppress EMT. The panel mRNA expression levels of E ‐ cadherin and Vimentin were investigated, and the Vimentin / E ‐ cadherin ratio was calculated. In MKN7 cells, Vimentin mRNA expression was higher, and E ‐ cadherin mRNA expression was lower compared to other TSPAN31‐overexpressing cell lines. (C) Knockdown of TSPAN31 induced significant morphological change, increased the expression of E‐cadherin protein, and reduced the expression of Vimentin and Snail proteins

Article Snippet: The abundance of mRNA was measured by quantitative PCR using a StepOnePlus PCR System (Applied Biosystems), and cycle threshold (Ct) values were calculated with StepOne Software version 2.0 (Applied Biosystems) using TaqMan Gene Expression Assays (Hs00919595_g1 for TSPAN31 , Hs00170423_m1 for E ‐ cadherin , Hs00958111_m1 for Vimentin , Hs00960489_m1 for ABCC2 ; Applied Biosystems) according to the manufacturer’s instructions.

Techniques: Migration, Knockdown, Mutagenesis, MANN-WHITNEY, Expressing

Improvement in chemosensitivity by Tetraspanin31 (TSPAN31) knockdown in gastric cancer (GC) cells. (A) When treated with cisplatin (CDDP), transfection of TP53 WT NUGC4 and TP53 mutant MKN74 cells with siRNA‐TSPAN31 increased early apoptosis 48 h posttransfection compared to treatment with CDDP or transfection with control siRNA alone. (B) Knockdown of TSPAN31 suppressed ABCC2 expression in both NUGC4 (WT TP53 ) and MKN74 (mutant TP53 ) GC cells. Moreover, the distribution of TSPAN31 in GC cells was similar to that of ABCC2. (C) Knockdown of TSPAN31 induced a significant decrease in the mRNA expression level of ABCC2 . (D) Co‐immunoprecipitation (IP) showed TSPAN31 complexed with ABCC2 in NUGC4

Journal: Cancer Science

Article Title: Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer

doi: 10.1111/cas.15342

Figure Lengend Snippet: Improvement in chemosensitivity by Tetraspanin31 (TSPAN31) knockdown in gastric cancer (GC) cells. (A) When treated with cisplatin (CDDP), transfection of TP53 WT NUGC4 and TP53 mutant MKN74 cells with siRNA‐TSPAN31 increased early apoptosis 48 h posttransfection compared to treatment with CDDP or transfection with control siRNA alone. (B) Knockdown of TSPAN31 suppressed ABCC2 expression in both NUGC4 (WT TP53 ) and MKN74 (mutant TP53 ) GC cells. Moreover, the distribution of TSPAN31 in GC cells was similar to that of ABCC2. (C) Knockdown of TSPAN31 induced a significant decrease in the mRNA expression level of ABCC2 . (D) Co‐immunoprecipitation (IP) showed TSPAN31 complexed with ABCC2 in NUGC4

Article Snippet: The abundance of mRNA was measured by quantitative PCR using a StepOnePlus PCR System (Applied Biosystems), and cycle threshold (Ct) values were calculated with StepOne Software version 2.0 (Applied Biosystems) using TaqMan Gene Expression Assays (Hs00919595_g1 for TSPAN31 , Hs00170423_m1 for E ‐ cadherin , Hs00958111_m1 for Vimentin , Hs00960489_m1 for ABCC2 ; Applied Biosystems) according to the manufacturer’s instructions.

Techniques: Knockdown, Transfection, Mutagenesis, Control, Expressing, Immunoprecipitation